QTTB Q32 Bio Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1661998 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY176.6%
TTM EPS YoY210.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE24.0%
ROA18.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3.2%
Debt / equity0.00x
Current ratio56.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.62x
Accruals ratio29.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $0 |
| R&D expense | $5.15M | $4.26M | $3.22M | $3.31M | $3.56M | $5.16M | $7.12M | $10.54M |
| SG&A expense | $5.51M | $4.86M | $4.50M | $4.54M | $4.02M | $4.01M | $5.10M | $3.98M |
| Operating income | -$10.66M | -$9.12M | -$7.72M | $45.88M | -$7.58M | -$9.17M | -$12.23M | -$14.53M |
| Pretax income | — | — | — | $57.73M | -$7.39M | -$9.49M | -$11.03M | -$14.17M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $21,000 |
| Net income | -$8.92M | -$8.95M | -$7.61M | $57.73M | -$7.39M | -$9.49M | -$11.03M | -$14.19M |
| EBITDA | -$10.56M | -$9.02M | -$7.63M | $45.97M | -$7.48M | -$9.07M | -$12.11M | -$14.41M |
| EPS (basic) | -0.26 | -0.44 | -0.54 | — | -0.60 | -0.78 | -0.90 | — |
| EPS (diluted) | -0.26 | -0.44 | -0.54 | — | -0.60 | -0.78 | -0.90 | — |
| Weighted avg. shares (diluted) | 34.02M | 20.34M | 14.10M | — | 12.24M | 12.20M | 12.20M | — |
| Banking | ||||||||
| Net interest income | — | -$246,000 | -$192,000 | $1.93M | -$220,000 | -$284,000 | -$371,000 | $5.00M |
| Balance sheet | ||||||||
| Cash & equivalents | $289.59M | $106.27M | $50.75M | $48.30M | $49.04M | $54.83M | $65.48M | $78.61M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Current assets | $291.13M | $109.65M | $57.20M | $55.05M | $50.81M | $58.32M | $68.63M | $81.88M |
| PP&E, net | $827,000 | $804,000 | $889,000 | $979,000 | $1.07M | $1.16M | $1.25M | $1.37M |
| Total assets | $297.20M | $115.87M | $63.67M | $61.78M | $57.78M | $66.12M | $79.07M | $92.33M |
| Current liabilities | $5.17M | $5.40M | $10.67M | $11.35M | $11.11M | $11.53M | $14.58M | $16.46M |
| Total liabilities | $9.53M | $9.96M | $17.36M | $19.76M | $76.23M | $78.35M | $83.08M | $86.66M |
| Shareholders' equity | $287.67M | $105.91M | $46.31M | $42.01M | -$18.45M | -$12.23M | -$4.01M | $5.67M |
| Shares outstanding | 29.89M | 23.74M | 14.63M | 12.86M | 12.30M | 12.20M | 12.20M | 12.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.42M | -$3.08M | -$6.34M | -$6.18M | -$4.23M | -$10.65M | -$12.48M | -$11.43M |
| Capital expenditure | — | — | — | $0 | $0 | — | — | $2,000 |
| Free cash flow | — | — | — | -$6.18M | -$4.23M | — | — | -$11.43M |
| Investing cash flow | -$52,000 | $0 | $0 | $7.00M | $0 | $0 | $0 | -$2,000 |
| Financing cash flow | $187.79M | $58.59M | $8.80M | -$1.56M | -$1.56M | — | — | $317,000 |
| Depreciation & amortization | $100,000 | $100,000 | $90,000 | $90,000 | $100,000 | $100,000 | $119,000 | $120,000 |
| Stock-based compensation | $2.90M | $1.69M | $1.55M | $1.47M | $1.18M | $1.27M | $1.34M | $1.25M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.